Recursion Pharmaceuticals, Inc.

NasdaqGS:RXRX 주식 리포트

시가총액: US$1.8b

Recursion Pharmaceuticals 경영진

경영진 기준 점검 1/4

Recursion Pharmaceuticals CEO는 Najat Khan, Jan2026 에 임명되었습니다 의 임기는 1년 미만입니다. 총 연간 보상은 $9.19M, 3.1% 급여 및 96.9% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $137.24K 가치에 해당하는 회사 주식의 0.008% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 1.5 년과 10.6 년입니다.

핵심 정보

Najat Khan

최고경영자

US$9.2m

총 보수

CEO 급여 비율3.10%
CEO 재임 기간less than a year
CEO 지분 보유율0.008%
경영진 평균 재임 기간1.5yrs
이사회 평균 재임 기간10.6yrs

최근 경영진 업데이트

Recent updates

News Flash: 9 Analysts Think Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Earnings Are Under Threat

May 04
News Flash: 9 Analysts Think Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Earnings Are Under Threat

Recursion Pharmaceuticals! WTH is going on?

Recursion Pharmaceuticals (RXRX) one day will be the Palantir of biotechnology! With the CMO transitioning out as well as the former CEO RXRX now has a chance to take off!

Recursion Pharmaceuticals May Be Losing Ground To Its Peers

Apr 28

RXRX: Later Launch And Higher Costs Will Set Up Cleaner Upside

Analysts have trimmed their price target on Recursion Pharmaceuticals to $6 from $7, citing updated operating expense and share count assumptions, as well as a later expected launch timeline for REC-617. Analyst Commentary Bullish analysts point out that the recent cut to a US$6 price target still reflects confidence in Recursion Pharmaceuticals reaching key development milestones over time, even with updated expense forecasts and a later expected REC-617 launch.

Recursion Pharmaceuticals! WTH is going on?

I was very pessimistic about RXRX! I am now extremely optimistic and here’s why!

RXRX: Later Launch Assumptions Will Set Up Cleaner Long Term Upside

Analysts recently trimmed their 12 month price target for Recursion Pharmaceuticals to $6 from $7, citing revised operating expense assumptions, a higher share count, and a later expected launch timing for REC-617. Analyst Commentary Recent commentary around Recursion Pharmaceuticals has focused on updated assumptions for operating expenses, a higher share count, and a later expected launch for REC-617.

RXRX: Later Launch And Cleaner Model Assumptions Will Support Long Term Upside

Analysts have lowered their price target on Recursion Pharmaceuticals to $6 from $7, citing updated operating expense assumptions, a revised share count, and a later expected launch timing for REC-617. Analyst Commentary While the latest research includes a lower price target, recent commentary still highlights areas where bullish analysts see room for Recursion Pharmaceuticals to execute and create value over time.

RXRX: FAP Data And Cautious Outlook Will Support Long Term Thesis

Analysts have trimmed their price target for Recursion Pharmaceuticals to $6 from $7, citing revised estimates, updated operating expense and share count assumptions, and a later expected launch for REC-617. Analyst Commentary Recent commentary points to a more cautious tone on Recursion Pharmaceuticals, with the latest price target reset to reflect updated expense planning, share count expectations, and a later potential launch for REC-617.

Recursion Pharmaceuticals! WTH is going on?

As I see what RXRX did in the 4th quarter I now believe they will be the Palantir of biotechnology one day! Najat Khan the new CEO will lead this company out of the hole created by the former CEO into greatness!

RXRX: FAP Trial Success Will Support Future Margin Expansion Potential

Analysts have maintained their $7.00 price target on Recursion Pharmaceuticals, citing broadly consistent long term assumptions and only minor adjustments to the discount rate, profit margin outlook, and future P/E multiple. What's in the News Recursion reported positive Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an allosteric MEK1/2 inhibitor being studied for familial adenomatous polyposis, with REC-4881 4 mg QD linked to rapid clinical activity in the trial population (Key Developments).

RXRX: Positive FAP Trial Data Will Support Stronger Long Term Thesis

Analysts have raised their price target on Recursion Pharmaceuticals to US$11.00, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E as the key drivers of the change. What's in the News Recursion reported positive Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis.

RXRX: Positive FAP Trial Results Will Support Future Margin Expansion

Analysts have modestly adjusted their price target on Recursion Pharmaceuticals, citing updated assumptions around the discount rate, long-term revenue growth, profit margin, and future P/E. Together, these revisions lead to a refined fair value estimate of US$7.00 per share.

RXRX: Positive FAP Trial Data Will Support Stronger Long Term Thesis

Analysts have lifted their fair value estimate for Recursion Pharmaceuticals from US$10.00 to US$11.00, citing updated assumptions around revenue growth, profit margin, and future P/E levels as key drivers of the new target. What's in the News Recursion reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (Key Developments).

RXRX: Positive TUPELO Data Will Drive Future AI-Enabled Margin Expansion

Analysts have raised their price target on Recursion Pharmaceuticals by approximately 10 percent to around 7.00 dollars per share, citing a modestly higher fair value estimate despite tempered revenue growth assumptions. What's in the News Announced positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, with 75 percent of evaluable patients showing reduced total polyp burden and a 43 percent median reduction after 12 weeks of treatment (Key Developments).

RXRX: New CEO Appointment Will Spark Stronger Margins And AI-Driven Momentum

Analysts have modestly raised their price target for Recursion Pharmaceuticals from $6.30 to $6.33 per share. They cite improved forecasted revenue growth and higher profit margins as key drivers behind the update.

RXRX: Leadership Change Will Drive Future Opportunity Amid Accelerating Revenue Outlook

Analysts have lowered their price target for Recursion Pharmaceuticals from $6.47 to $6.30, citing adjustments in projected discount rates and profit margins despite stronger expected revenue growth. What's in the News Dr. Najat Khan has been appointed as Chief Executive Officer of Recursion Pharmaceuticals, effective January 1, 2026 (Key Developments).

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates

Nov 07
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates

Recursion: FDA To Replace Animal Testing With AI? - A Small But Necessary Win

Apr 11

Recursion: A Look At Near-Term Phase 1b And Phase 2 Catalysts

Mar 27
User avatar

REC-617 And REC-994 Trials Will Drive Future AI-Driven Drug Discovery Success

Successful clinical trials and expanded pipeline indicate promising future revenue growth and earnings from potential drug market entries.

Recursion Pharmaceuticals: Stretched Thin And Chasing Unicorns

Mar 12

This Just In: Analysts Are Boosting Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Outlook for This Year

Mar 02
This Just In: Analysts Are Boosting Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Outlook for This Year

Recursion Pharmaceuticals Needs A Clinical Breakthrough To Pique Interest

Feb 14

Recursion: Investors Will Need To Be Patient

Jan 10

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Dec 25
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245

Dec 09

Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline

Nov 20

Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week

Nov 10
Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk

Nov 08
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk

Recursion: AI Is Only As Good As The Data

Sep 11

CEO 보수 분석

Najat Khan의 보수는 Recursion Pharmaceuticals의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Dec 31 2025n/an/a

-US$645m

Sep 30 2025n/an/a

-US$716m

Jun 30 2025n/an/a

-US$649m

Mar 31 2025n/an/a

-US$575m

Dec 31 2024US$9mUS$285k

-US$464m

보상 대 시장: Najat의 총 보수(USD9.19M)는 US 시장에서 비슷한 규모 기업의 평균(USD5.48M)보다 높습니다.

보상과 수익: Najat의 보상을 회사 실적과 비교하기에 데이터가 부족합니다.

CEO

Najat Khan (41 yo)

less than a year
재임 기간
US$9,194,804
보수

Dr. Najat Khan, Ph D is Chief Executive Officer and President of Recursion Pharmaceuticals, Inc. January 1, 2026. She was Chief R&D Officer and Chief Commercial Officer of Recursion Pharmaceuticals, Inc. f...

리더십 팀

이름직위재임 기간보수지분
Christopher Gibson
Co-Founder12.5yrsUS$8.50m1.04%
$ 18.4m
Najat Khan
CEO, President & Directorless than a yearUS$9.19m0.0077%
$ 137.2k
Ben Taylor
CFO & President of Recursion UK1.5yrsUS$8.59m0.049%
$ 867.4k
David Mauro
Advisor2.9yrsUS$1.93m0.014%
$ 251.2k
Kristen Rushton
Chief Operating Officer1.5yrs데이터 없음데이터 없음
Benjamin Mabey
Chief Technology Officer6.3yrs데이터 없음데이터 없음
David Hallett
Chief Scientific Officer1.5yrs데이터 없음0.072%
$ 1.3m
Nathan Hatfield
Chief Legal Officer & Corporate Secretary2.6yrs데이터 없음데이터 없음
Ryan Kelly
Chief Communications Officerno data데이터 없음데이터 없음
Erica Fox
Chief People and Impact Officer1.5yrs데이터 없음데이터 없음
Matthew Kinn
Chief Business Officer1.5yrs데이터 없음데이터 없음
Sid Jain
Senior Vice President of Clinical Development & Data Scienceless than a year데이터 없음데이터 없음
1.5yrs
평균 재임 기간
45yo
평균 나이

경험이 풍부한 관리: RXRX의 경영진은 경험이 부족한 것으로 간주됩니다(평균 재임 1.5 년) — 신규 팀일 수 있습니다.

이사회 구성원

이름직위재임 기간보수지분
Christopher Gibson
Co-Founder12.5yrsUS$8.50m1.04%
$ 18.4m
Najat Khan
CEO, President & Director2.1yrsUS$9.19m0.0077%
$ 137.2k
Robert Lollini
Member of Business Advisory Panel11.5yrs데이터 없음데이터 없음
H. Fell
Member of Business Advisory Panel11.9yrs데이터 없음데이터 없음
Joseph Miletich
Chairman of Therapeutics Advisory Board4.8yrs데이터 없음데이터 없음
Robert Hershberg
Vice-Chairman & Lead Independent Director6.2yrsUS$316.48k0.0098%
$ 174.3k
Dean Li
Directorless than a yearUS$296.73k0.61%
$ 10.8m
Blake Borgeson
Independent Director13.3yrsUS$294.98k1.18%
$ 20.9m
Anne Carpenter
Member of Scientific and Technical Advisory Board12.1yrs데이터 없음데이터 없음
Kirk Thomas
Member of Scientific & Technical Advisory Board12.1yrs데이터 없음데이터 없음
Zavain Dar
Independent Director9.7yrsUS$304.23k0.024%
$ 422.0k
Elaine Sun
Independent Director1.2yrs데이터 없음데이터 없음
10.6yrs
평균 재임 기간
57.5yo
평균 나이

경험이 풍부한 이사회: RXRX의 이사회는 노련하고 경험이 풍부합니다(평균 재임 10.6 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/06 22:54
종가2026/05/06 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Recursion Pharmaceuticals, Inc.는 13명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Gal MundaBerenberg
Gaurav GoparajuBerenberg
Alec StranahanBofA Global Research